Pharmaceuticals North America (NAFTA) Industry Guide 2015-2024
Pharmaceuticals North America (NAFTA) Industry Guide 2015-2024
SUMMARY
The NAFTA Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Essential resource for top-line data and analysis covering the NAFTA pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.
KEY HIGHLIGHTS
SUMMARY
The NAFTA Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Essential resource for top-line data and analysis covering the NAFTA pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.
KEY HIGHLIGHTS
- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The pharmaceuticals industry within the NAFTA countries had a total market value of $438.4 billion in 2019.The US was the fastest growing country, with a CAGR of 3.4% over the 2015-19 period.
- Within the pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of $409.4 billion in 2019. This was followed by Canada and Mexico, with a value of $23.8 and $5.3 billion, respectively.
- The US is expected to lead the pharmaceuticals industry in the NAFTA bloc, with a value of $417.2 billion in 2024, followed by Canada and Mexico with expected values of $26.8 and $5.5 billion, respectively.
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA pharmaceuticals market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA pharmaceuticals market
- Leading company profiles reveal details of key pharmaceuticals market players’ NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA pharmaceuticals market with five year forecasts
- Compares data from the US, Canada and Mexico, alongside individual chapters on each country
- What was the size of the NAFTA pharmaceuticals market by value in 2019?
- What will be the size of the NAFTA pharmaceuticals market in 2024?
- What factors are affecting the strength of competition in the NAFTA pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitors in the NAFTA pharmaceuticals market?
1 INTRODUCTION
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 NAFTA PHARMACEUTICALS
2.1. Industry Outlook
3 PHARMACEUTICALS IN CANADA
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
3.6. Macroeconomic Indicators
4 PHARMACEUTICALS IN MEXICO
4.1. Market Overview
4.2. Market Data
4.3. Market Segmentation
4.4. Market outlook
4.5. Five forces analysis
4.6. Macroeconomic Indicators
5 PHARMACEUTICALS IN THE UNITED STATES
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
5.6. Macroeconomic Indicators
6 COMPANY PROFILES
6.1. Johnson & Johnson
6.2. Pfizer Inc.
6.3. Apotex Pharmachem Inc
6.4. Merck & Co., Inc.
6.5. Bayer AG
6.6. Novartis AG
6.7. AstraZeneca AB
7 APPENDIX
7.1. Methodology
7.2. About MarketLine
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 NAFTA PHARMACEUTICALS
2.1. Industry Outlook
3 PHARMACEUTICALS IN CANADA
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
3.6. Macroeconomic Indicators
4 PHARMACEUTICALS IN MEXICO
4.1. Market Overview
4.2. Market Data
4.3. Market Segmentation
4.4. Market outlook
4.5. Five forces analysis
4.6. Macroeconomic Indicators
5 PHARMACEUTICALS IN THE UNITED STATES
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
5.6. Macroeconomic Indicators
6 COMPANY PROFILES
6.1. Johnson & Johnson
6.2. Pfizer Inc.
6.3. Apotex Pharmachem Inc
6.4. Merck & Co., Inc.
6.5. Bayer AG
6.6. Novartis AG
6.7. AstraZeneca AB
7 APPENDIX
7.1. Methodology
7.2. About MarketLine
LIST OF TABLES
Table 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2015-24
Table 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2015-19
Table 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2019-24
Table 4: Canada pharmaceuticals market value: $ billion, 2015-19
Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2019
Table 6: Canada pharmaceuticals market share: % share, by value, 2019
Table 7: Canada pharmaceuticals market value forecast: $ billion, 2019-24
Table 8: Canada size of population (million), 2015-19
Table 9: Canada gdp (constant 2005 prices, $ billion), 2015-19
Table 10: Canada gdp (current prices, $ billion), 2015-19
Table 11: Canada inflation, 2015-19
Table 12: Canada consumer price index (absolute), 2015-19
Table 13: Canada exchange rate, 2015-19
Table 14: Mexico pharmaceuticals market value: $ billion, 2015-19
Table 15: Mexico pharmaceuticals market geography segmentation: $ billion, 2019
Table 16: Mexico pharmaceuticals market share: % share, by value, 2019
Table 17: Mexico pharmaceuticals market value forecast: $ billion, 2019-24
Table 18: Mexico size of population (million), 2015-19
Table 19: Mexico gdp (constant 2005 prices, $ billion), 2015-19
Table 20: Mexico gdp (current prices, $ billion), 2015-19
Table 21: Mexico inflation, 2015-19
Table 22: Mexico consumer price index (absolute), 2015-19
Table 23: Mexico exchange rate, 2015-19
Table 24: United States pharmaceuticals market value: $ billion, 2015-19
Table 25: United States pharmaceuticals market geography segmentation: $ billion, 2019
Table 26: United States pharmaceuticals market share: % share, by value, 2019
Table 27: United States pharmaceuticals market value forecast: $ billion, 2019-24
Table 28: United States size of population (million), 2015-19
Table 29: United States gdp (constant 2005 prices, $ billion), 2015-19
Table 30: United States gdp (current prices, $ billion), 2015-19
Table 31: United States inflation, 2015-19
Table 32: United States consumer price index (absolute), 2015-19
Table 33: United States exchange rate, 2015-19
Table 34: Johnson & Johnson: key facts
Table 35: Johnson & Johnson: Annual Financial Ratios
Table 36: Johnson & Johnson: Key Employees
Table 37: Johnson & Johnson: Key Employees Continued
Table 38: Pfizer Inc.: key facts
Table 39: Pfizer Inc.: Annual Financial Ratios
Table 40: Pfizer Inc.: Key Employees
Table 41: Pfizer Inc.: Key Employees Continued
Table 42: Apotex Pharmachem Inc: key facts
Table 43: Apotex Pharmachem Inc: Key Employees
Table 44: Merck & Co., Inc.: key facts
Table 45: Merck & Co., Inc.: Annual Financial Ratios
Table 46: Merck & Co., Inc.: Key Employees
Table 47: Merck & Co., Inc.: Key Employees Continued
Table 48: Bayer AG: key facts
Table 49: Bayer AG: Annual Financial Ratios
Table 50: Bayer AG: Key Employees
Table 51: Novartis AG: key facts
Table 52: Novartis AG: Annual Financial Ratios
Table 53: Novartis AG: Annual Financial Ratios (Continued)
Table 54: Novartis AG: Key Employees
Table 55: Novartis AG: Key Employees Continued
Table 56: AstraZeneca AB: key facts
Table 57: AstraZeneca AB: Key Employees
Table 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2015-24
Table 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2015-19
Table 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2019-24
Table 4: Canada pharmaceuticals market value: $ billion, 2015-19
Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2019
Table 6: Canada pharmaceuticals market share: % share, by value, 2019
Table 7: Canada pharmaceuticals market value forecast: $ billion, 2019-24
Table 8: Canada size of population (million), 2015-19
Table 9: Canada gdp (constant 2005 prices, $ billion), 2015-19
Table 10: Canada gdp (current prices, $ billion), 2015-19
Table 11: Canada inflation, 2015-19
Table 12: Canada consumer price index (absolute), 2015-19
Table 13: Canada exchange rate, 2015-19
Table 14: Mexico pharmaceuticals market value: $ billion, 2015-19
Table 15: Mexico pharmaceuticals market geography segmentation: $ billion, 2019
Table 16: Mexico pharmaceuticals market share: % share, by value, 2019
Table 17: Mexico pharmaceuticals market value forecast: $ billion, 2019-24
Table 18: Mexico size of population (million), 2015-19
Table 19: Mexico gdp (constant 2005 prices, $ billion), 2015-19
Table 20: Mexico gdp (current prices, $ billion), 2015-19
Table 21: Mexico inflation, 2015-19
Table 22: Mexico consumer price index (absolute), 2015-19
Table 23: Mexico exchange rate, 2015-19
Table 24: United States pharmaceuticals market value: $ billion, 2015-19
Table 25: United States pharmaceuticals market geography segmentation: $ billion, 2019
Table 26: United States pharmaceuticals market share: % share, by value, 2019
Table 27: United States pharmaceuticals market value forecast: $ billion, 2019-24
Table 28: United States size of population (million), 2015-19
Table 29: United States gdp (constant 2005 prices, $ billion), 2015-19
Table 30: United States gdp (current prices, $ billion), 2015-19
Table 31: United States inflation, 2015-19
Table 32: United States consumer price index (absolute), 2015-19
Table 33: United States exchange rate, 2015-19
Table 34: Johnson & Johnson: key facts
Table 35: Johnson & Johnson: Annual Financial Ratios
Table 36: Johnson & Johnson: Key Employees
Table 37: Johnson & Johnson: Key Employees Continued
Table 38: Pfizer Inc.: key facts
Table 39: Pfizer Inc.: Annual Financial Ratios
Table 40: Pfizer Inc.: Key Employees
Table 41: Pfizer Inc.: Key Employees Continued
Table 42: Apotex Pharmachem Inc: key facts
Table 43: Apotex Pharmachem Inc: Key Employees
Table 44: Merck & Co., Inc.: key facts
Table 45: Merck & Co., Inc.: Annual Financial Ratios
Table 46: Merck & Co., Inc.: Key Employees
Table 47: Merck & Co., Inc.: Key Employees Continued
Table 48: Bayer AG: key facts
Table 49: Bayer AG: Annual Financial Ratios
Table 50: Bayer AG: Key Employees
Table 51: Novartis AG: key facts
Table 52: Novartis AG: Annual Financial Ratios
Table 53: Novartis AG: Annual Financial Ratios (Continued)
Table 54: Novartis AG: Key Employees
Table 55: Novartis AG: Key Employees Continued
Table 56: AstraZeneca AB: key facts
Table 57: AstraZeneca AB: Key Employees
LIST OF FIGURES
Figure 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2015-24
Figure 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2015-19
Figure 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2019-24
Figure 4: Canada pharmaceuticals market value: $ billion, 2015-19
Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 6: Canada pharmaceuticals market share: % share, by value, 2019
Figure 7: Canada pharmaceuticals market value forecast: $ billion, 2019-24
Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2019
Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2019
Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2019
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2019
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2019
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2019
Figure 14: Mexico pharmaceuticals market value: $ billion, 2015-19
Figure 15: Mexico pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 16: Mexico pharmaceuticals market share: % share, by value, 2019
Figure 17: Mexico pharmaceuticals market value forecast: $ billion, 2019-24
Figure 18: Forces driving competition in the pharmaceuticals market in Mexico, 2019
Figure 19: Drivers of buyer power in the pharmaceuticals market in Mexico, 2019
Figure 20: Drivers of supplier power in the pharmaceuticals market in Mexico, 2019
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2019
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2019
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2019
Figure 24: United States pharmaceuticals market value: $ billion, 2015-19
Figure 25: United States pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 26: United States pharmaceuticals market share: % share, by value, 2019
Figure 27: United States pharmaceuticals market value forecast: $ billion, 2019-24
Figure 28: Forces driving competition in the pharmaceuticals market in the United States, 2019
Figure 29: Drivers of buyer power in the pharmaceuticals market in the United States, 2019
Figure 30: Drivers of supplier power in the pharmaceuticals market in the United States, 2019
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2019
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2019
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2019
COMPANIES MENTIONED
Johnson & Johnson
Pfizer Inc.
Apotex Pharmachem Inc
Merck & Co., Inc.
Bayer AG
Novartis AG
AstraZeneca AB
Figure 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2015-24
Figure 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2015-19
Figure 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2019-24
Figure 4: Canada pharmaceuticals market value: $ billion, 2015-19
Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 6: Canada pharmaceuticals market share: % share, by value, 2019
Figure 7: Canada pharmaceuticals market value forecast: $ billion, 2019-24
Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2019
Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2019
Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2019
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2019
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2019
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2019
Figure 14: Mexico pharmaceuticals market value: $ billion, 2015-19
Figure 15: Mexico pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 16: Mexico pharmaceuticals market share: % share, by value, 2019
Figure 17: Mexico pharmaceuticals market value forecast: $ billion, 2019-24
Figure 18: Forces driving competition in the pharmaceuticals market in Mexico, 2019
Figure 19: Drivers of buyer power in the pharmaceuticals market in Mexico, 2019
Figure 20: Drivers of supplier power in the pharmaceuticals market in Mexico, 2019
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2019
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2019
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2019
Figure 24: United States pharmaceuticals market value: $ billion, 2015-19
Figure 25: United States pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 26: United States pharmaceuticals market share: % share, by value, 2019
Figure 27: United States pharmaceuticals market value forecast: $ billion, 2019-24
Figure 28: Forces driving competition in the pharmaceuticals market in the United States, 2019
Figure 29: Drivers of buyer power in the pharmaceuticals market in the United States, 2019
Figure 30: Drivers of supplier power in the pharmaceuticals market in the United States, 2019
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2019
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2019
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2019
COMPANIES MENTIONED
Johnson & Johnson
Pfizer Inc.
Apotex Pharmachem Inc
Merck & Co., Inc.
Bayer AG
Novartis AG
AstraZeneca AB
